The DOI matches its Crossref record; 63 of the 70 references it cites were found in a registry or an index.
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Open accessAbstract
The switch to an angiogenic phenotype is a fundamental determinant of neoplastic growth and tumor progression. We demonstrate that homozygous deletion of the p53 tumor suppressor gene via homologous recombination in a human cancer cell line promotes the neovascularization and growth of tumor xenografts in nude mice. We find that p53 promotes Mdm2-mediated ubiquitination and proteasomal degradation of the HIF-1α subunit of hypoxia-inducible factor 1 (HIF-1), a heterodimeric transcription factor that regulates cellular energy metabolism and angiogenesis in response to oxygen deprivation. Loss of p53 in tumor cells enhances HIF-1α levels and augments HIF-1-dependent transcriptional activation of the vascular endothelial growth factor (VEGF) gene in response to hypoxia. Forced expression of HIF-1α in p53-expressing tumor cells increases hypoxia-induced VEGF expression and augments neovascularization and growth of tumor xenografts. These results indicate that amplification of normal HIF-1-dependent responses to hypoxia via loss of p53 function contributes to the angiogenic switch during tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apart from canonical HRE-mediated transcription, the HIF isoforms differentially modulate signaling pathways through interaction with proteins that do not contain PAS domains, such p53, the c-MYC proto-oncogene, β-catenin and the Notch intracellular domain (Fig. 2A) [11–15].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Intriguingly, p53 can also promote Mdm2-mediated degradation of HIF-1α (Ravi et al., 2000).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Ravi et al., 2000
The cited source says what the claim attributes to it.
In the citing paper
“It has been proposed that MDM2 can also ubiquitinate and degrade HIF-1α through the proteasome pathway”
From Stress Response of Glioblastoma Cells Mediated by miR-17-5p Targeting PTEN and the Passenger Strand miR-17-3p Targeting MDM2 (2012) · cites this paper as [56]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“which raises the possibility that miR-17 mediates cellular response to diverse stimuli by targeting closely related signaling pathways [56].”
From Stress Response of Glioblastoma Cells Mediated by miR-17-5p Targeting PTEN and the Passenger Strand miR-17-3p Targeting MDM2 (2012) · cites this paper as [56]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Self-citationThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“…ligase and is itself a target for Ub-mediated degradation via its interaction with Mdm2 (Momand et al. 1992; Barak et al. 1993; Wu et al. 1993; Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997), this raised the possibility that HIF-1a is recruited to Mdm2 via its interaction with p53.”
Background
Flagged first, then by citations
7 of the 70 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Kubbutat, 1997, Regulation of p53 stability by Mdm2., Nature, 387, 299, 10.1038/387299a0 · DOI · Paper page
- Ravi, 1998, p53-mediated repression of nuclear factor κ-B RelA via the transcriptional integrator p 300., Cancer Res., 58, 4531
- Zhong, 1999, Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases., Cancer Res., 59, 5830
Cited by
Sorted by citations
Items 601–700 of 967
The potential roles of p53 signaling reactivation in pancreatic cancer therapy
Ou, A., Zhao, X., & Lu, Z. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188662 · Cited by 30
The Underestimated Role of the p53 Pathway in Renal Cancer
Amendolare, A., Marzano, F., Petruzzella, V., Vacca, R. A., Guerrini, L., Pesole, G., Sbisà, E., & Tullo, A. (2022) · Cancers · doi:10.3390/cancers14235733 · Cited by 31
Özcan, G. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1082057 · Cited by 31
Neo-vascularization-based therapeutic perspectives in advanced ovarian cancer
Bhardwaj, V., Zhang, X., Pandey, V., & Garg, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188888 · Cited by 29
A novel regulation of VEGF expression by HIF‐1α and STAT3 in HDM2 transfected prostate cancer cells
Rathinavelu, A., Narasimhan, M., & Muthumani, P. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01472.x · Cited by 28
Pentamidine reduces expression of hypoxia-inducible factor-1α in DU145 and MDA-MB-231 cancer cells
Jung, H.-J., Suh, S., Suh, M., Baek, W., & Park, J. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.008 · Cited by 28
Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze
Olivares, O., & Vasseur, S. (2015) · International Journal of Cancer · doi:10.1002/ijc.29501 · Cited by 28
Protein kinase CK2 inhibition is associated with the destabilization of HIF-1α in human cancer cells
Guerra, B., Rasmussen, T., Schnitzler, A., Jensen, H. H., Boldyreff, B., Miyata, Y., Marcussen, N., Niefind, K., & Issinger, O. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.026 · Cited by 28
siRNA: an alternative treatment for diabetes and associated conditions
Shende, P. K., & Patel, C. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1476518 · Cited by 28
Chauhan, S., Jaiswal, S., Jakhmola, V., Singh, B. P., Bhattacharya, S., Garg, M., & Sengupta, S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216766 · Cited by 29
Improving Wound Healing with Topical Gene Therapy
Layliev, J., Wilson, S. C., Warren, S. M., & Saadeh, P. B. (2012) · Advances in Wound Care · doi:10.1089/wound.2011.0322 · Cited by 28
Lim, J.-H., Park, J., Kim, S. J., Kim, M.-S., Park, S.-K., Johnson, R. S., & Chun, Y. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.030296 · Cited by 28
Hagland, H. R., Nikolaisen, J., Hodneland, L., Gjertsen, B. T., Bruserud, Ø., & Tronstad, K. J. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.8.1055 · Cited by 27
Singh, M., Devi, U., Roy, S., Gupta, P. S., Saraf, S. A., & Kaithwas, G. (2016) · Breast Cancer · doi:10.1007/s12282-016-0683-6 · Cited by 28
Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression
Wang, Z., Zhao, Y., An, Z., & Li, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01491 · Cited by 26
Yao, S., Meric‐Bernstam, F., Hong, D. S., Jankú, F., Naing, A., Piha-Paul, S. A., Tsimberidou, A. M., Karp, D. D., Subbiah, V., Yap, T. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-12669-5 · Cited by 27
Hypoxia‐Inducible Factor‐1 as a Therapeutic Target in Endometrial Cancer Management
Seeber, L. M. S., Zweemer, R. P., Verheijen, R. H. M., & van Diest, P. J. (2010) · Obstetrics and Gynecology International · doi:10.1155/2010/580971 · Cited by 27
Lee, W., Lan, K., Li, C., Chao, Y., Lin, H., & Lee, S. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.023 · Cited by 27
Chowers, I., Folberg, R., Livni, N., & Pe’er, J. (2002) · Current Eye Research · doi:10.1076/ceyr.24.2.105.8166 · Cited by 27
Regulation of the HIF switch in human endothelial and cancer cells
Slawski, J., Jaśkiewicz, M., Barton, A., Kozioł, S., Collawn, J. F., & Bartoszewski, R. (2024) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2024.151386 · Cited by 26
Choi, J., Cho, H. K., Choi, Y. H., & Cheong, J. (2009) · Biochemical Journal · doi:10.1042/bj20090371 · Cited by 24
Babaei, G., Aliarab, A., Vostakolaei, M. A., Hotelchi, M., Neisari, R., Aziz, S. G., & Bazl, M. R. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06706-1 · Cited by 29
PFKFB4 interacts with FBXO28 to promote HIF-1α signaling in glioblastoma
Phillips, E. S., Balß, J., Bethke, F., Pusch, S., Christen, S., Hielscher, T., Schnölzer, M., Fletcher, M. N. C., Habel, A., Tessmer, C., et al. (2022) · Oncogenesis · doi:10.1038/s41389-022-00433-3 · Cited by 26
Jeong, J., & Park, S. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.10.086 · Cited by 26
PKB/Akt activation inhibits p53‐mediated HIF1A degradation that is independent of MDM2
Choy, M., Movassagh, M., Bennett, M. R., & Foo, R. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21980 · Cited by 28
Lee, J.-H., Jin, Y., He, G., Zeng, S. X., Wang, Y. V., Wahl, G. M., & Lu, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.336875 · Cited by 25
Fang, J. S., Cao, Z., Chen, Y., Reed, E., & Jiang, B. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.1.178 · Cited by 27
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Klasa, R. J., List, A. F., & Cheson, B. D. (2001) · Hematology · doi:10.1182/asheducation-2001.1.443 · Cited by 26
Recent Insights into Roles of Hypoxia-Inducible Factors in Retinal Diseases
Lee, D., Tomita, Y., Miwa, Y., Kunimi, H., Nakai, A., Shoda, C., Negishi, K., & Kurihara, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810140 · Cited by 26
Epigenetic modulators mitigate angiogenesis through a complex transcriptomic network
Shankar, T. V. S., & Willems, L. (2014) · Vascular Pharmacology · doi:10.1016/j.vph.2014.01.003 · Cited by 25
Martin, A. R., Ronco, C., Demange, L., & Benhida, R. (2016) · MedChemComm · doi:10.1039/c6md00432f · Cited by 27
Genetics of recurrent pregnancy loss among Iranian population
Moghbeli, M. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.891 · Cited by 25
Yan, Q., Chen, P., Wang, S., Liu, N., Zhao, P., & Gu, A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-950 · Cited by 24
Cho, S.-J., Teng, I.-F., Zhang, M., Yin, T., Jung, Y., Zhang, J., & Chen, X. (2014) · Oncotarget · doi:10.18632/oncotarget.2786 · Cited by 27
Gupta, V. K., Jaiswara, P. K., Sonker, P., Rawat, S. G., Tiwari, R. K., & Kumar, A. (2019) · APOPTOSIS · doi:10.1007/s10495-019-01585-1 · Cited by 24
Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy
Rada, M., Qusairy, Z., Massip‐Salcedo, M., & Macip, S. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0814 · Cited by 24
Sun, M., Jiang, H., Liu, T., Tan, X., Jiang, Q., Sun, B., Zheng, Y., Wang, G., Wang, Y., Cheng, M., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.008 · Cited by 24
The Proteasome: Destroy to Live
Abramova, E. B., Sharova, N. P., & Карпов, В. Л. (2002) · Molecular Biology · doi:10.1023/a:1020654926226 · Cited by 24
Sumoylation of hypoxia inducible factor-1α and its significance in cancer
Li, J., Xu, Y., Jiao, H., Wang, W., Mei, Z., & Chen, G. (2014) · Science China Life Sciences · doi:10.1007/s11427-014-4685-3 · Cited by 25
HIF-1 : régulateur central de l’hypoxie
Gothié, E., & Pouysségur, J. (2002) · médecine/sciences · doi:10.1051/medsci/200218170 · Cited by 38
MicroRNA target site polymorphisms in the VHL‐HIF1α pathway predict renal cell carcinoma risk
Wei, H., Ke, H., Lin, J. M., Shete, S. S., Wood, C. G., & Hildebrandt, M. A. T. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.21917 · Cited by 24
Chen, S., HU, C., Yang, D., Nassief, A. M., Chen, H., Yin, K., Xu, J., & Hsu, C. Y. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1338.033 · Cited by 24
Xu, Y.-R., Wang, A.-L., & Li, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.984525 · Cited by 23
Bartkowiak, K., Riethdorf, S., & Pantel, K. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0067-6 · Cited by 23
Ali, A., Coulter, J. A., Ogle, C. H., Migaud, M. E., Hirst, D. G., Robson, T., & McCarthy, H. O. (2013) · Bioscience Reports · doi:10.1042/bsr20120120 · Cited by 25
RetractedHypoxia-Induced Cytosine Deaminase Gene Expression for Cancer Therapy
Lee, C., Wu, C., & Shiau, A. (2007) · Human Gene Therapy · doi:10.1089/hum.2005.239 · Cited by 23
Horrée, N., Gort, E. H., van der Groep, P., Heintz, A. P. M., Vooijs, M., & van Diest, P. J. (2007) · The Journal of Pathology · doi:10.1002/path.2244 · Cited by 23
Rempe, D. A., Lelli, K. M., Vangeison, G., Johnson, R. S., & Federoff, H. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702203200 · Cited by 23
Tumour proliferation, angiogenesis, and ploidy status in human colon cancer
Cristi, E., Perrone, G., Toscano, G., Verzì, A., Nori, S., Santini, D., Tonini, G., Vetrani, A., Fabiano, A., & Rabitti, C. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.025536 · Cited by 23
p53 Checkpoint-Defective Cells Are Sensitive to X Rays, but Not Hypoxia
Denko, N. C., Green, S., Edwards, D., & Giaccia, A. J. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4928 · Cited by 23
Luo, B., Song, L., Chen, L., Cai, Y., Zhang, M., & Wang, S. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155675 · Cited by 23
Sansone, P., Storci, G., Pandolfi, S., Montanaro, L., Chieco, P., & Bonafè, M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603723 · Cited by 22
Hypoxia‐inducible factors – regulation, role and comparative aspects in tumourigenesis
Hansen, A. E., Kristensen, A. T., Law, I. G., Jørgensen, J. T., & Engelholm, S. A. (2010) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2010.00233.x · Cited by 23
Ostrakhovitch, E. A., Song, Y., & Cherian, M. G. (2016) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2016.01.008 · Cited by 23
DUBs, New Members in the Hypoxia Signaling clUb
Schober, A. S., & Berra, E. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00053 · Cited by 22
Yoon, A. R., Hong, J., Kim, M., & Yun, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-20268-6 · Cited by 22
Wang, Y., Jankú, F., Piha-Paul, S. A., Hess, K. R., Broaddus, R. R., Liu, L., Shi, N., Overman, M. J., Kopetz, S., Subbiah, V., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58366-z · Cited by 22
Ko, H., Jung, H. H., Seo, K. H., Kang, Y., Kim, H., Park, S. J., Lee, H.-K., & Im, S. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.04.042 · Cited by 22
Katoh, R. (2003) · Microscopy Research and Technique · doi:10.1002/jemt.10256 · Cited by 22
Antiangiogenic therapy for primary and metastatic brain tumors
Purow, B. W., & Fine, H. A. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2004.05.003 · Cited by 22
Characterization of the 5′ and 3′ untranslated regions in murine mdm2 mRNAs
Mendrysa, S. M., McElwee, M. K., & Perry, M. E. (2001) · Gene · doi:10.1016/s0378-1119(00)00589-8 · Cited by 22
Kim, S. S., Harford, J. B., Moghe, M., Doherty, C. L., & Chang, E. H. (2022) · Cells · doi:10.3390/cells11213434 · Cited by 23
Alam, M. M., Fermin, J. M., Knackstedt, M., Noonan, M. J., Powell, T., Goodreau, L., Daniel, E. K., Rong, X., Moore‐Medlin, T., Khandelwal, A. R., et al. (2023) · Oncotarget · doi:10.18632/oncotarget.28355 · Cited by 24
Yamada, T., KAMIYA, M., HIGUCHI, M., & NAKANISHI, N. (2018) · Journal of Veterinary Medical Science · doi:10.1292/jvms.18-0324 · Cited by 22
SALIDO, E. C., Timson, D. J., Betancor-Fernández, I., Palomino‐Morales, R., Anoz‐Carbonell, E., Pacheco‐García, J. L., Medina, M., & Pey, A. L. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050747 · Cited by 22
Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions
Jones, D. T., & Harris, A. L. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.674516 · Cited by 21
Oxygen sensing: applications in humans
Cherniack, N. S. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00755.2003 · Cited by 21
Si, Y., Ou, H., Jin, X., Gu, M., Sheng, S., Peng, W., Yang, D., Zhan, X., Zhang, L., Yu, Q., et al. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.06.021 · Cited by 20
Ting, K. K. Y. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1403915 · Cited by 20
A brief tour guide to cancer disease
Bisoyi, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99883-3.00006-8 · Cited by 20
Capillaries as a Therapeutic Target for Heart Failure
Yoshida, Y., Shimizu, I., & Minamino, T. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17064 · Cited by 21
Yi, L., Liu, J., Yang, H., Mo, A., Zhai, Y., Wang, S., & Yuan, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911198 · Cited by 19
Ma, J., Xue, Y., Cui, W., Li, Y., Zhao, Q., Ye, W., Zheng, J., Cheng, Y., Ma, Y., Li, S., et al. (2012) · Cancer · doi:10.1002/cncr.27393 · Cited by 20
Timani, K. A., Liu, Y., Fan, Y., Mohammad, K. S., & He, J. J. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00001-15 · Cited by 20
Park, S. Y., JUNG, C. H., SONG, B., Park, O. J., & Kim, Y. (2013) · Oncology Letters · doi:10.3892/ol.2013.1533 · Cited by 20
Liu, B., Liu, Q., Song, Y., Li, X., Wang, Y., Wan, S., Zhang, Z., & Su, H. (2014) · Medical Oncology · doi:10.1007/s12032-014-0877-8 · Cited by 20
Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review
Kifle, Z. D. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100116 · Cited by 20
Notch and the p53 Clan of Transcription Factors
Roemer, K. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0899-4_17 · Cited by 20
Gene Expression Induced by BO-653, Probucol and BHQ in Human Endothelial Cells
Takabe, W., Mataki, C., Wada, Y., Ishii, M., Izumi, A., Aburatani, H., Hamakubo, T., Niki, E., Kodama, T., & Noguchi, N. (2000) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat1994.7.223 · Cited by 20
Chettouh-Hammas, N., & Grillon, C. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.06.015 · Cited by 19
Kokubun, T., Saitoh, S., Miura, S., Ishida, T., & Takeishi, Y. (2019) · International Heart Journal · doi:10.1536/ihj.18-564 · Cited by 19
Modern Therapeutic Approaches in Metastatic Renal Cell Carcinoma
Staehler, M. D., Haseke, N., Schöppler, G., Stadler, T., Gratzke, C., & Stief, C. G. (2006) · EAU-EBU Update Series · doi:10.1016/j.eeus.2006.08.004 · Cited by 19
Sarma, P. N., Ramaiah, M. J., Pal, D., Bhadra, U., & Bhadra, M. P. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.03.024 · Cited by 19
Kuchimaru, T., Suka, T., Hirota, K., Kadonosono, T., & Kizaka‐Kondoh, S. (2016) · Scientific Reports · doi:10.1038/srep34311 · Cited by 19
Intracellular signalling and cancer: complex pathways lead to multiple targets
Bell, H. S., & Ryan, K. M. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.10.022 · Cited by 20
Myocardial Angiogenesis: Its Absence Makes the Growing Heart Founder
Dorn, G. W. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.04.003 · Cited by 19
Transition of autophagy and apoptosis in fibroblasts depends on dominant expression of HIF-1α or p53
Li, M., Su, Y., Gao, X., Yu, J., Wang, Z., & Wang, X. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2100187 · Cited by 18
Oxygen sensors as therapeutic targets in kidney disease
Haase, V. H. (2017) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2017.01.015 · Cited by 18
Romero, I., Rubio, M. J., Medina, M. H., Matías‐Guiu, X., Santacana, M., Schoenenberger, J.-A., Guerra, E., Cortés, A., Minig, L., Coronado, P., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.09.013 · Cited by 18
Lipid Metabolism in Cancer Cells
Zheng, M., Wang, W., Liu, J., Zhang, X., & Zhang, R. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6785-2_4 · Cited by 19
p53 codon 72 polymorphism and recurrent pregnancy loss: a meta-analysis
Tang, W., Zhou, X., Chan, Y., Wu, X., & Luo, Y. (2011) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-011-9618-5 · Cited by 18
Angiogenesis in ovarian cancer: Molecular pathology and therapeutic strategies
Paley, P. J. (2002) · Current Oncology Reports · doi:10.1007/s11912-002-0078-z · Cited by 18
Antiangiogenic Therapy and p53
Hammond, E. M., & Giaccia, A. J. (2002) · Science · doi:10.1126/science.297.5581.471a · Cited by 18
Hypoxia A Typical Target in Human Lung Cancer Therapy
Ullah, A., Shehzadi, S., Ullah, N., Nawaz, T., Iqbal, H., & Aziz, T. (2023) · Current Protein and Peptide Science · doi:10.2174/0113892037252820231114045234 · Cited by 17
Liu, S., Liu, Z., Lei, H., Miao, Y., & Chen, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202403019 · Cited by 17
Govekar, R. B., Dcruz, A. K., Pathak, K. A., Agarwal, J., Dinshaw, K. A., Chinoy, R. F., Gadewal, N. S., Kannan, S., Sirdeshmukh, R., Sundaram, C. S., et al. (2009) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200900023 · Cited by 17
Tamma, R., Ruggieri, S., Annese, T., Simone, G., Mangia, A., Rega, S., Zito, F. A., Nico, B., & Ribatti, D. (2018) · Oncotarget · doi:10.18632/oncotarget.25220 · Cited by 17
Regulation of epithelial‐to‐mesenchymal transition in hypoxia by the HIF‐1α network
Wang, H., Zhang, X., & Wang, W. (2021) · FEBS Letters · doi:10.1002/1873-3468.14258 · Cited by 17
Wilson, K. M., & He, J. J. (2022) · Aging and Disease · doi:10.14336/ad.2022.0712 · Cited by 16
The Angiogenic Switch in Tumorigenesis
WICKI, A. N., & Christofori, G. (2007) · Springer eBooks · doi:10.1007/978-3-540-33177-3_4 · Cited by 17
Metadata
- Authors
- Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A.
- Affiliations
- Johns Hopkins University (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2000-01-01
- Volume
- 14
- Issue
- 1
- Pages
- 34-44
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W4294718043
- Semantic Scholar
- 5c0770cda1be256df47794076979768b0350af33
- Cited by
- 967
- References
- 70
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 35 · 2023: 28 · 2022: 35 · 2021: 35 · 2020: 33 · 2019: 25 · 2018: 30 · 2017: 25 · 2016: 35 · 2015: 41 · 2014: 36 · 2013: 34 · 2012: 32
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- Funders
- U.S. Department of Defense
- American Cancer Society
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- tumor angiogenesis, p53, hypoxia-inducible factor-1α, MDM2, ubiquitination, proteasomal degradation, vascular endothelial growth factor, hypoxia, neovascularization, tumor xenografts, angiogenic switch, tumor suppressor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
